Your browser doesn't support javascript.
loading
Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.
Atreya, Mihir R; Whitacre, Brynne E; Cvijanovich, Natalie Z; Bigham, Michael T; Thomas, Neal J; Schwarz, Adam J; Weiss, Scott L; Fitzgerald, Julie C; Allen, Geoffrey L; Lutfi, Riad; Nowak, Jeffrey E; Quasney, Michael W; Shah, Amy S; Wong, Hector R.
Afiliación
  • Atreya MR; Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center and Cincinnati Children's Research Foundation, Cincinnati, OH.
  • Whitacre BE; Department of Pathobiology and Laboratory Medicine, University of Cincinnati, College of Medicine, Cincinnati, OH.
  • Cvijanovich NZ; UCSF Benioff Children's Hospital Oakland, Oakland, CA.
  • Bigham MT; Akron Children's Hospital, Akron, OH.
  • Thomas NJ; Penn State Hershey Children's Hospital, Hershey, PA.
  • Schwarz AJ; Children's Hospital of Orange County, Orange, CA.
  • Weiss SL; The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Fitzgerald JC; The Children's Hospital of Philadelphia, Philadelphia, PA.
  • Allen GL; Children's Mercy Hospital, Kansas City, MO.
  • Lutfi R; Riley Hospital for Children, Indianapolis, IN.
  • Nowak JE; Children's Hospital and Clinics of Minnesota, Minneapolis, MN.
  • Quasney MW; CS Mott Children's Hospital at the University of Michigan, Ann Arbor, MI.
  • Shah AS; Division of Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
  • Wong HR; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
Crit Care Med ; 48(10): 1513-1520, 2020 10.
Article en En | MEDLINE | ID: mdl-32769621
ABSTRACT

OBJECTIVES:

Proprotein convertase subtilisin/kexin type 9 is a central regulator of lipid metabolism and has been implicated in regulating the host response to sepsis. Proprotein convertase subtilisin/kexin type 9 loss-of-function is associated with improved sepsis outcomes in the adult host through increased hepatic bacterial clearance. Thus, there is interest in leveraging proprotein convertase subtilisin/kexin type 9 inhibitors as a therapeutic strategy in adults with sepsis. We sought to validate this association in children with septic shock and in a juvenile murine model of sepsis.

DESIGN:

Prospectively enrolled cohort of children with septic shock; experimental mice.

SETTING:

Seventeen participating institutions; research laboratory. PATIENTS AND

SUBJECTS:

Five-hundred twenty-two children with septic shock; juvenile (14 d old) and adult (10-14 wk) mice with constitutive proprotein convertase subtilisin/kexin type 9 null and wildtype control mice (C57BL/6).

INTERVENTIONS:

Proprotein convertase subtilisin/kexin type 9 single-nucleotide polymorphisms, serum proprotein convertase subtilisin/kexin type 9, and lipid profiles in patients. Cecal slurry murine model of sepsis; survival studies in juvenile and adult mice, assessment of lipoprotein fractions, bacterial burden, and inflammation in juvenile mice. MEASUREMENTS AND MAIN

RESULTS:

PCSK9 loss-of-function genetic variants were independently associated with increased odds of complicated course and mortality in children with septic shock. PCSK9, low-density lipoprotein, and high-density lipoprotein concentrations were lower among patients with complicated course relative to those without. PCSK9 concentrations negatively correlated with proinflammatory cytokine interleukin-8. Proprotein convertase subtilisin/kexin type 9 loss-of-function decreased survival in juvenile mice, but increased survival in adult mice with sepsis. PCSK9 loss-of-function resulted in low lipoproteins and decreased hepatic bacterial burden in juvenile mice.

CONCLUSIONS:

In contrast to the adult host, proprotein convertase subtilisin/kexin type 9 loss-of-function is detrimental to the juvenile host with septic shock. PCSK9 loss-of-function, in the context of low lipoproteins, may result in reduced hepatic bacterial clearance in the juvenile host with septic shock. Our data indicate that children should be excluded in sepsis clinical trials involving proprotein convertase subtilisin/kexin type 9 inhibitors.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Choque Séptico / Proproteína Convertasa 9 / Lípidos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Crit Care Med Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Choque Séptico / Proproteína Convertasa 9 / Lípidos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Crit Care Med Año: 2020 Tipo del documento: Article